ERBB2 and aneurysmal bone cyst: The results of the present meta-analysis demonstrated that sorafenib-based therapies provide a clinically modest, but statistically significant, PFS benefit (HR, 0.78; 95% CI, 0.54–1.02) in HER2-negative ABC patients.